hotspot -WSS

hotspot

author：hotspot 2025-09-07 17:29:39 - browse：8418

Allergan, Dom Smith/STAT

It wasn’t supposed to work out this way for Brent Saunders.

Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Making the case for fair compensation in clinical trials

WSS

Scrutiny of post

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

H5N1 virus can be tracked in retail milk, scientists say

Cue Health, Covid

As a primary care physician, here's how I hope to partner with AI

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

hotspot

hotspot

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Study finds gene variants tied to breast cancer risk in Black women

The high cost of giving birth even with insurance

H5N1 bird flu outbreak: Second human case reported, in Michigan

How to save PrEP access — and even expand it

Inside the culture of fear in the White House science office of Eric Lander

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How a key Senate committee is planning to regulate PBMs

Medical leaders decry Supreme Court decision on affirmative action

FDA approves first blood sugar monitor without finger pricks

entertainment

New requirements coming in 2024 for Americans traveling to Europe

Digital health: a case of mistaken identity

Fentanyl is making it harder to start addiction treatment

Making the case for fair compensation in clinical trials

Citing H5N1 threat, CDC urges peak flu monitoring this summer

How to protect coverage of PrEP

hotspot

explore

hotspot

Wikipedia